Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics:

• Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00)
• Biology and Current Clinical Management of PNH (36:35)
• Future Directions in PNH Management (55:34)
• Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26)

CME information and select publications

Featuring an interview with Dr Emmanuel S Antonarakis, including the following topics:

• Perspectives on advances in the management of prostate cancer over the last decade (0:00)
• Nonmetastatic high-risk prostate cancer and androgen deprivation therapy (ADT) intensification with abiraterone: Insights from the STAMPEDE trial (7:39)
• EMBARK: A Phase III trial of enzalutamide or placebo with leuprolide acetate and enzalutamide monotherapy for high-risk biochemically recurrent prostate cancer (15:25)
• Quality of life and preservation of sexual function with enzalutamide monotherapy compared to ADT alone or enzalutamide with ADT (20:20)
• Management of locally advanced prostate cancer with and without biochemical recurrence (23:58)
• PRESTO trial of ADT intensification with apalutamide with or without abiraterone for high-risk biochemically relapsed prostate cancer (30:35)
• CDK4/6 inhibitors, proteolysis-targeting chimeras and other novel therapeutic approaches for targeting androgen receptor signaling in prostate cancer (31:41)
• Choice of endocrine partner with ADT and incorporation of docetaxel in the treatment of metastatic hormone-sensitive prostate cancer (35:38)
• Other potential novel therapeutic strategies for prostate cancer (42:28)
• Integration of genomic testing for patients with prostate cancer; PARP inhibitor combinations for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (43:57)
• Incorporation of radiopharmaceuticals (ie, lutetium Lu 177 vipivotide tetraxetan, radium-223) into the management of prostate cancer (52:49)
• Perspectives on the results of the Phase III CONTACT-02 trial evaluating cabozantinib in combination with atezolizumab for mCRPC (57:44)

CME information and select publications

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:

• Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00)
• Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35)
• Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21)
• Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10)
• Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33)
• Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38)
• Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08)
• Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56)
• Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48)
• Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18)
• Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56)

CME information and select publications